Statement: Bristol-Myers Squibb on the 2019 Novel Coronavirus

Wednesday, February 5, 2020 10:45 am EST



In response to the global health emergency concerning the spread of the 2019 Novel Coronavirus (2019-nCoV), Bristol-Myers Squibb has taken several steps to protect the health and safety of our colleagues, ensure that patients experience no disruption to the supply of their medicines and provide frontline medical professionals with the support they need to contain and fight the virus. Here are some actions we have taken to date:

  • Per recommendations from the CDC (Centers for Disease Control and Prevention), we have limited and restricted employee travel to and from China;
  • We are diligently monitoring manufacturing and supply facilities across the globe and we do not expect any disruptions to the supply of our medicines for patients;
  • Bristol-Myers Squibb has donated approximately $750,000 in cash and needed products to Wuhan city and Hubei province, through the Shanghai Red Cross Society;
  • The Bristol-Myers Squibb Foundation, a 501(c)(3) organization, has separately provided support to two relief partner organizations to provide more than one million items of personal protection, including masks, gloves and coveralls, to healthcare professionals in Renmin and Zhongnan hospitals in Wuhan City; and
  • The BMS Foundation is working closely with our partners to ensure medical supplies are quickly distributed to frontline medical professionals treating patients in Wuhan.

Bristol-Myers Squibb is committed to the safety of our employees and patients across the globe. We will continue to monitor the situation closely.

For further inquiries, please contact

Privacy Policy
Business Wire NewsHQsm